{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:32:43Z","timestamp":1786624363601,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["222300420518"],"award-info":[{"award-number":["222300420518"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"crossref","award":["202208410226"],"award-info":[{"award-number":["202208410226"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03721-6","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T08:36:00Z","timestamp":1766738160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Differential complement pathways and components in the clinical spectrum of systemic lupus erythematosus"],"prefix":"10.1186","volume":"28","author":[{"given":"Haijun","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"3721_CR1","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","volume":"403","author":"A Hoi","year":"2024","unstructured":"Hoi A, Igel T, Mok CC, et al. Systemic lupus erythematosus. Lancet. 2024;403:2326\u201338.","journal-title":"Lancet"},{"key":"3721_CR2","doi-asserted-by":"publisher","first-page":"e149095","DOI":"10.1172\/JCI149095","volume":"131","author":"Y Atisha-Fregoso","year":"2021","unstructured":"Atisha-Fregoso Y, Toz B, Diamond B. Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. J Clin Invest. 2021;131:e149095.","journal-title":"J Clin Invest"},{"key":"3721_CR3","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2665-9913(22)00332-0","volume":"5","author":"M Shipa","year":"2022","unstructured":"Shipa M, Santos LR, Nguyen DX, et al. Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus. Lancet Rheumatol. 2022;5:e24\u201335.","journal-title":"Lancet Rheumatol"},{"key":"3721_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.rdc.2021.04.006","volume":"47","author":"SP Canny","year":"2021","unstructured":"Canny SP, Jackson SW. B cells in systemic lupus erythematosus: from disease mechanisms to targeted therapies. Rheum Dis Clin North Am. 2021;47:395\u2013413.","journal-title":"Rheum Dis Clin North Am"},{"key":"3721_CR5","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.ekir.2021.06.016","volume":"6","author":"C Cantarelli","year":"2021","unstructured":"Cantarelli C, Leventhal J, Cravedi P. Complement in lupus: Biomarker, therapeutic Target, or a little bit of both? Kidney Int Rep. 2021;6:2031\u201332.","journal-title":"Kidney Int Rep"},{"key":"3721_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","volume":"10","author":"X Dai","year":"2025","unstructured":"Dai X, Fan Y, Zhao X. Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics. Signal Transduct Target Ther. 2025;10:102.","journal-title":"Signal Transduct Target Ther"},{"key":"3721_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13075-025-03536-5","volume":"27","author":"M Calatroni","year":"2025","unstructured":"Calatroni M, Conte E, Stella M, et al. Clinical and immunological biomarkers can identify proliferative changes and predict renal flares in lupus nephritis. Arthritis Res Ther. 2025;27:72.","journal-title":"Arthritis Res Ther"},{"key":"3721_CR8","doi-asserted-by":"publisher","first-page":"e000209","DOI":"10.1136\/lupus-2017-000209","volume":"4","author":"IJ Gandino","year":"2017","unstructured":"Gandino IJ, Scolnik M, Bertiller E, et al. Complement levels and risk of organ involvement in patients with systemic lupus erythematosus. Lupus Sci Med. 2017;4:e000209.","journal-title":"Lupus Sci Med"},{"key":"3721_CR9","doi-asserted-by":"publisher","first-page":"582737","DOI":"10.3389\/fimmu.2020.582737","volume":"11","author":"M Martin","year":"2020","unstructured":"Martin M, Trattner R, Nilsson SC, et al. Plasma C4d correlates with C4d deposition in kidneys and with treatment response in lupus nephritis patients. Front Immunol. 2020;11:582737.","journal-title":"Front Immunol"},{"key":"3721_CR10","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/art.40747","volume":"71","author":"AHJ Kim","year":"2019","unstructured":"Kim AHJ, Strand V, Sen DP, et al. Association of blood concentrations of complement split product iC3b and serum C3 with systemic lupus erythematosus disease activity. Arthritis Rheumatol. 2019;71:420\u201330.","journal-title":"Arthritis Rheumatol"},{"key":"3721_CR11","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/art.1780350907","volume":"35","author":"JP Buyon","year":"1992","unstructured":"Buyon JP, Tamerius J, Belmont HM, Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum. 1992;35:1028\u201337.","journal-title":"Arthritis Rheum"},{"key":"3721_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ebiom.2018.05.034","volume":"32","author":"H Ma","year":"2018","unstructured":"Ma H, Liu C, Shi B, et al. Mesenchymal stem cells control complement C5 activation by factor H in lupus nephritis. EBioMedicine. 2018;32:21\u201330.","journal-title":"EBioMedicine"},{"key":"3721_CR13","doi-asserted-by":"publisher","first-page":"e0186414","DOI":"10.1371\/journal.pone.0186414","volume":"12","author":"T Asano","year":"2017","unstructured":"Asano T, Ito H, Kariya Y, et al. Evaluation of blood-brain barrier function by quotient alpha2 macroglobulin and its relationship with interleukin-6 and complement component 3 levels in neuropsychiatric systemic lupus erythematosus. PLoS ONE. 2017;12:e0186414.","journal-title":"PLoS ONE"},{"key":"3721_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4049\/jimmunol.2200540","volume":"210","author":"C Kemper","year":"2023","unstructured":"Kemper C, Ferreira VP, Paz JT, et al. Complement: the road less traveled. J Immunol. 2023;210:119\u201325.","journal-title":"J Immunol"},{"key":"3721_CR15","doi-asserted-by":"publisher","first-page":"e2350918","DOI":"10.1002\/eji.202350918","volume":"54","author":"MC Pickering","year":"2024","unstructured":"Pickering MC, Botto M. Canonical and noncanonical functions of complement in systemic lupus erythematosus. Eur J Immunol. 2024;54:e2350918.","journal-title":"Eur J Immunol"},{"key":"3721_CR16","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1177\/0961203320925165","volume":"29","author":"H Kim","year":"2020","unstructured":"Kim H, Kim T, Kim M, et al. Activation of the alternative complement pathway predicts renal outcome in patients with lupus nephritis. Lupus. 2020;29:862\u201371.","journal-title":"Lupus"},{"key":"3721_CR17","first-page":"231","volume":"14","author":"N Saadati","year":"2023","unstructured":"Saadati N, Miri M. Evaluation of serum C4d levels in patients with systemic lupus erythematosus and its relation to lupus nephritis. Casp J Intern Med. 2023;14:231\u20136.","journal-title":"Casp J Intern Med"},{"key":"3721_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.amjms.2017.01.005","volume":"353","author":"D Song","year":"2017","unstructured":"Song D, Guo WY, Wang FM, et al. Complement alternative Pathway\u05f3s activation in patients with lupus nephritis. Am J Med Sci. 2017;353:247\u201357.","journal-title":"Am J Med Sci"},{"key":"3721_CR19","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American college of rheumatology revised criteria for systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.","journal-title":"Arthritis Rheum"},{"key":"3721_CR20","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288\u201391.","journal-title":"J Rheumatol"},{"key":"3721_CR21","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","volume":"1","author":"V Golder","year":"2019","unstructured":"Golder V, Kandane-Rathnayake R, Huq M, et al. Lupus low disease activity state as a treatment endpoint for SLE. Lancet Rheumatol. 2019;1:e95\u2013102.","journal-title":"Lancet Rheumatol"},{"key":"3721_CR22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"BH Hahn","year":"2012","unstructured":"Hahn BH, McMahon MA, Wilkinson A, et al. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64:797\u2013808.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3721_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1749-6632.2009.04921.x","volume":"1173","author":"A Ceribelli","year":"2009","unstructured":"Ceribelli A, Andreoli L, Cavazzana I, et al. Complement cascade in systemic lupus erythematosus: analyses of the three activation pathways. Ann N Y Acad Sci. 2009;1173:427\u201334.","journal-title":"Ann N Y Acad Sci"},{"key":"3721_CR24","first-page":"11","volume":"69","author":"VD Pradhan","year":"2021","unstructured":"Pradhan VD, Khadilkar PV, Nadkar MY, et al. Impact of autoantibodies to complement components on SLE disease activity. J Assoc Physicians India. 2021;69:11\u20132.","journal-title":"J Assoc Physicians India"},{"key":"3721_CR25","first-page":"408","volume":"36","author":"K Whaley","year":"1979","unstructured":"Whaley K, Schur PH, Ruddy S. Modulation of the Properdin amplification loop in SLE. Clin Exp Immunol. 1979;36:408\u201314.","journal-title":"Clin Exp Immunol"},{"key":"3721_CR26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/ard.45.5.359","volume":"45","author":"AJ Swaak","year":"1986","unstructured":"Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis. 1986;45:359\u201366.","journal-title":"Ann Rheum Dis"},{"key":"3721_CR27","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.semnephrol.2015.08.006","volume":"35","author":"DJ Birmingham","year":"2015","unstructured":"Birmingham DJ, Hebert LA. The complement system in lupus nephritis. Semin Nephrol. 2015;35:444\u201354.","journal-title":"Semin Nephrol"},{"key":"3721_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.molimm.2015.05.007","volume":"68","author":"L Truedsson","year":"2015","unstructured":"Truedsson L. Classical pathway deficiencies - A short analytical review. Mol Immunol. 2015;68:14\u20139.","journal-title":"Mol Immunol"},{"key":"3721_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jaut.2013.01.003","volume":"42","author":"R Huda","year":"2013","unstructured":"Huda R, T\u00fcz\u00fcn E, Christadoss P. Complement C2 SiRNA mediated therapy of myasthenia Gravis in mice. J Autoimmun. 2013;42:94\u2013104.","journal-title":"J Autoimmun"},{"key":"3721_CR30","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jaci.2020.08.028","volume":"147","author":"I Van de Walle","year":"2021","unstructured":"Van de Walle I, Silence K, Budding K, et al. ARGX-117, a therapeutic complement inhibiting antibody targeting C2. J Allergy Clin Immunol. 2021;147:1420\u201329.","journal-title":"J Allergy Clin Immunol"},{"key":"3721_CR31","doi-asserted-by":"publisher","first-page":"fcac306","DOI":"10.1093\/braincomms\/fcac306","volume":"4","author":"CI Campbell","year":"2022","unstructured":"Campbell CI, McGonigal R, Barrie JA, et al. Complement Inhibition prevents glial nodal membrane injury in a GM1 antibody-mediated mouse model. Brain Commun. 2022;4:fcac306.","journal-title":"Brain Commun"},{"key":"3721_CR32","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/nrrheum.2012.75","volume":"8","author":"G Sturfelt","year":"2012","unstructured":"Sturfelt G, Truedsson L. Complement in the Immunopathogenesis of rheumatic disease. Nat Rev Rheumatol. 2012;8:458\u201368.","journal-title":"Nat Rev Rheumatol"},{"key":"3721_CR33","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1191\/0961203304lu1080oa","volume":"13","author":"M Ramos-Casals","year":"2004","unstructured":"Ramos-Casals M, Campoamor MT, Chamorro A, et al. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus. 2004;13:777\u201383.","journal-title":"Lupus"},{"key":"3721_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00281-014-0428-6","volume":"36","author":"OP Rekvig","year":"2014","unstructured":"Rekvig OP, Van der Vlag J. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin Immunopathol. 2014;36:301\u201311.","journal-title":"Semin Immunopathol"},{"key":"3721_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMra2206346","volume":"388","author":"A Mantovani","year":"2023","unstructured":"Mantovani A, Garlanda C. Humoral innate immunity and Acute-Phase proteins. N Engl J Med. 2023;388:439\u201352.","journal-title":"N Engl J Med"},{"key":"3721_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000233593","volume":"75","author":"G Sturfelt","year":"1984","unstructured":"Sturfelt G, Sj\u00f6holm AG. Complement components, complement activation, and acute phase response in systemic lupus erythematosus. Int Arch Allergy Appl Immunol. 1984;75:75\u201383.","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"3721_CR37","doi-asserted-by":"publisher","first-page":"8051972","DOI":"10.1155\/2018\/8051972","volume":"2018","author":"W Raymond","year":"2018","unstructured":"Raymond W, Eilertsen G, Nossent J. Hypocomplementemia as a risk factor for organ damage accrual in patients with systemic lupus erythematosus. J Immunol Res. 2018;2018:8051972.","journal-title":"J Immunol Res"},{"key":"3721_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s42358-022-00283-y","volume":"62","author":"R Takamatsu","year":"2022","unstructured":"Takamatsu R, Shimojima Y, Kishida D, et al. The impact of normal serum complement levels on the disease classification and clinical characteristics in systemic lupus erythematosus. Adv Rheumatol. 2022;62:49.","journal-title":"Adv Rheumatol"},{"key":"3721_CR39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev.iy.13.040195.001425","volume":"13","author":"JE Volanakis","year":"1995","unstructured":"Volanakis JE. Transcriptional regulation of complement genes. Annu Rev Immunol. 1995;13:277\u2013305.","journal-title":"Annu Rev Immunol"},{"key":"3721_CR40","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.molimm.2019.05.012","volume":"112","author":"EA Bemis","year":"2019","unstructured":"Bemis EA, Norris JM, Seifert J, et al. Complement and its environmental determinants in the progression of human rheumatoid arthritis. Mol Immunol. 2019;112:256\u201365.","journal-title":"Mol Immunol"},{"key":"3721_CR41","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41588-024-02044-7","volume":"57","author":"H Loya","year":"2025","unstructured":"Loya H, Kalantzis G, Cooper F, et al. A scalable variational inference approach for increased mixed-model association power. Nat Genet. 2025;57:461\u20138.","journal-title":"Nat Genet"},{"key":"3721_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun BB, Chiou J, Traylor M, et al. Plasma proteomic associations with genetics and health in the UK biobank. Nature. 2023;622:329\u201338.","journal-title":"Nature"},{"key":"3721_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s41927-024-00395-6","volume":"8","author":"RA Abdel-Magied","year":"2024","unstructured":"Abdel-Magied RA, Mokhtar NW, Abdullah NM, et al. Infection versus disease activity in systemic lupus erythematosus patients with fever. BMC Rheumatol. 2024;8:34.","journal-title":"BMC Rheumatol"},{"key":"3721_CR44","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.2147\/JIR.S322391","volume":"14","author":"H Li","year":"2021","unstructured":"Li H, Chen J, Hu Y, et al. Serum C1q levels have prognostic value for sepsis and are related to the severity of sepsis and organ damage. J Inflamm Res. 2021;14:4589\u2013600.","journal-title":"J Inflamm Res"},{"key":"3721_CR45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semarthrit.2006.04.008","volume":"36","author":"CC Mok","year":"2006","unstructured":"Mok CC. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum. 2006;36:71\u201381.","journal-title":"Semin Arthritis Rheum"},{"key":"3721_CR46","doi-asserted-by":"publisher","first-page":"712572","DOI":"10.3389\/fimmu.2021.712572","volume":"12","author":"J Barratt","year":"2021","unstructured":"Barratt J, Weitz I. Complement factor D as a strategic target for regulating the alternative complement pathway. Front Immunol. 2021;12:712572.","journal-title":"Front Immunol"},{"key":"3721_CR47","doi-asserted-by":"publisher","first-page":"1007102","DOI":"10.3389\/fimmu.2022.1007102","volume":"13","author":"RJMGE Brandwijk","year":"2022","unstructured":"Brandwijk RJMGE, Michels MAHM, van Rossum M, et al. Pitfalls in complement analysis: A systematic literature review of assessing complement activation. Front Immunol. 2022;13:1007102.","journal-title":"Front Immunol"},{"key":"3721_CR48","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1309\/AJCPXPD7ZQXNTIAL","volume":"143","author":"S Yang","year":"2015","unstructured":"Yang S, McGookey M, Wang Y, et al. Effect of blood sampling, processing, and storage on the measurement of complement activation biomarkers. Am J Clin Pathol. 2015;143:558\u201365.","journal-title":"Am J Clin Pathol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03721-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03721-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03721-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:05:51Z","timestamp":1769785551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-025-03721-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3721"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03721-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"7 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Xinxiang Medical University (2018059), and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}